Structural variants and copy number

Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

George T, Staron A, Burks EJ, Szalat RE, Sanchorawala V

British Journal of Haematology208(6):2252-2255DOI: Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosisPubMed: Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

Genetic Predictors of Mortality in Patients with Multiple Myeloma

Hassan H, Szalat R

The Application of Clinical GeneticsVolume 14:241-254DOI: Genetic Predictors of Mortality in Patients with Multiple MyelomaPubMed: Genetic Predictors of Mortality in Patients with Multiple Myeloma

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Bazarbachi AH, Avet-Loiseau H, Szalat R, …, Samur MK

Blood138(20):1980-1985DOI: IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WMPubMed: IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study

Fillmore NR, Cirstea D, Munjuluri A, …, Szalat RE, Munshi NC

Blood Advances5(18):3511-3514DOI: Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA studyPubMed: Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, …, Szalat R, …, Gallardo M

Cancers13(13):3189DOI: Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple MyelomaPubMed: Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan G

Leukemia33(1):159-170DOI: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisPubMed: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan GJ

Blood132(6):587-597DOI: Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaPubMed: Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Expressed fusion gene landscape and its impact in multiple myeloma

Cleynen A, Szalat R, Samur MK, …, Avet-Loiseau H

Nature Communications8(1)DOI: Expressed fusion gene landscape and its impact in multiple myelomaPubMed: Expressed fusion gene landscape and its impact in multiple myeloma

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Fulciniti M, Martinez-Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

Blood129(16):2233-2245DOI: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaPubMed: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?

Aktas Samur A, Minvielle S, Fulciniti M, Szalat R, …, Samur M

HemaSphere3(S1):12DOI: S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?

Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications

Bolli N, Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

Haematologica103(S3):S51-S51

The chronological order of copy number changes in hyperdiploid multiple myeloma patients

Maura F, Bolli N, Dawson K, Angelopoulos N, Szalat R, Martincorena I, et al.

HEMASPHERE2(S1):727-727

The genomic landscape of structural variations and complex events in multiple myeloma

Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

Haematologica103(S3):S14-S14

The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis

Maura F, Leongamornlert D, Angelopoulos N, …, Szalat R, …, Bolli N

Blood132(Supplement 1):109-109DOI: The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis

Abnormalities in mitochondrial DNA copy number have pathogenetic and prognostic implications in multiple myeloma

Ruiz-Heredia Y, Samur MK, Ortiz-Ruiz A, Fernández RA, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):4378 …

The genomic landscape of multiple myeloma complex structural variations

Maura F, Bolli N, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):330-330

Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

Song XL, Szalat R, Talbot A, …, Bories JC

Blood128(22):4462-4462DOI: Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing

Szalat R, Bolli N, Maura F, …, Munshi NC

Blood128(22):236-236DOI: The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing

The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact

Cleynen A, Szalat R, Samur MK, Parmigiani G, Munshi NC, Avet-Loiseau H

Blood126(23):835-835DOI: The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact

Frequent Igh Fusion Transcripts with Clinical Impact in Multiple Myeloma

Cleynen A, Szalat R, Samur MK, Rashid N, Parmigiani G, Munshi NC, Avet-Loiseau H

Blood124(21):721-721DOI: Frequent Igh Fusion Transcripts with Clinical Impact in Multiple Myeloma

Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Arnulf B, Lazareth A, Soulier J, …, Szalat R, …, Fermand JP

Blood120(21):3971-3971DOI: Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation

Arnulf B, Szalat R, Karlin L, Harel S, Asli B, Malphettes M, Soulier J, Fermand JP

Blood118(21):4501-4501DOI: Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation